GHRP-2
GHRP-2 is a synthetic hexapeptide growth-hormone secretagogue also known as pralmorelin.
The short version
- Why people discuss it
- Discussed for growth-hormone signaling, recovery and appetite stimulation. Community interest does not establish benefit or a suitable treatment.
- What it is
- GHRP-2 is a synthetic hexapeptide growth-hormone secretagogue also known as pralmorelin.
- Biggest caution
- Diagnostic or acute hormone-response findings do not establish body-composition or performance benefits. Product identity, repeated-use effects and long-term safety remain unresolved.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–200 mcg
- Frequency
- Once nightly
- Duration / phase
- 8–12 weeks
Repeated bedtime example. Reports also describe 100–300 mcg two or three times daily as higher-frequency variants, not the same exposure. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
100–200 mcg SC once nightly; optional 250–300 mcg; 8–12 weeks.
- Peptidepedia — saved source reviewed September 27, 2026
100–300 mcg 1–3 times/day; most-common example 100–200 mcg bedtime, 8–12 weeks; higher frequency advanced.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27